EGFR inhibitors, such as gefitinib, lapatinib and afatinib, have been approved to treat cancers, but severe drug resistance of EGFR inhibitors leads to low clinical response, which may be caused by drug-induced EGFR mutations (e.g. EGFRL858R, EGFRT790M or EGFRC797S) [149]. This evidence concerns the gene EGFR and cancer.